Shanghai Allist Pharmaceuticals Co., Ltd. Overview
Pro stress-test →Shanghai Allist Pharmaceuticals is an innovation-oriented Chinese pharmaceutical company specializing in tumor-targeted drugs and therapies. Founded in 2004 and listed on the Shanghai Stock Exchange in December 2020, the company focuses on developing first-in-class and best-in-class oncology medicines addressing unmet global clinical needs.
Strategic Profile
Pro stress-test →Allist has established itself as a specialized oncology player with core competencies in lung cancer therapeutics. The company leverages both proprietary drug development capabilities and strategic in-licensing agreements to expand its pipeline, positioning itself to compete in the global pharmaceutical market while maintaining strong domestic commercialization channels.
Competitive Landscape
Pro stress-test →Allist competes within the oncology space against both domestic Chinese pharmaceutical companies and international players. Its primary competitive advantage rests in the lung cancer market where Furmonertinib has established a strong foothold. Major comparators include international standards like Osimertinib (AstraZeneca) and Afatinib, though Furmonertinib's clinical profile demonstrates superior mPFS in certain EGFR mutation subtypes.
Industry Context
Shanghai Allist Pharmaceuticals Co., Ltd. operates in Oncology Pharmaceuticals / Tumor-Targeted Drug Development.
Key facts
Founded: 2004 · Headquarters: Shanghai, China · Employees: 1,823 · Market cap: 47.4B CNY